QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NYSEAMERICAN:OCX

OncoCyte (OCX) Stock Forecast, Price & News

$1.16
+0.03 (+2.65%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.13
$1.20
50-Day Range
N/A
52-Week Range
$1.09
$6.25
Volume
349,169 shs
Average Volume
490,490 shs
Market Capitalization
$107.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.87
30 days | 90 days | 365 days | Advanced Chart
Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OncoCyte logo

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:OCX
Employees
110
Year Founded
N/A

Sales & Book Value

Annual Sales
$7.73 million
Book Value
$0.71 per share

Profitability

Net Income
$-64.10 million
Net Margins
-877.80%
Pretax Margin
-949.37%

Debt

Price-To-Earnings

Miscellaneous

Free Float
95,879,000
Market Cap
$107.01 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/11/2022
Today
5/16/2022
Next Earnings (Estimated)
5/16/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.42 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Is OncoCyte a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte
or view top-rated stocks.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022.
View our earnings forecast for OncoCyte
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) released its earnings results on Wednesday, May, 11th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. OncoCyte had a negative trailing twelve-month return on equity of 47.42% and a negative net margin of 877.80%.
View OncoCyte's earnings history
.

What price target have analysts set for OCX?

5 analysts have issued twelve-month price objectives for OncoCyte's stock. Their forecasts range from $1.40 to $6.00. On average, they expect OncoCyte's share price to reach $3.90 in the next twelve months. This suggests a possible upside of 236.2% from the stock's current price.
View analysts' price targets for OncoCyte
or view top-rated stocks among Wall Street analysts.

Who are OncoCyte's key executives?
OncoCyte's management team includes the following people:
  • Mr. Ronald A. Andrews Jr., CEO, Pres & Director (Age 62, Pay $978.35k)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Ms. Padma Sundar, Chief Commercial Officer
  • Ms. Gisela A. Paulsen, Chief Operating Officer
  • Ms. Li Yu, VP, Controller & Principal Accounting Officer
  • Dr. Ekkehard Schutz M.D., Ph.D., Chief Technology Officer
  • Mr. William Annett, Advisor (Age 68)
  • Dr. Douglas T. Ross M.D., Ph.D., Chief Science Officer
  • Mr. Robert S. Seitz, Head of Immune Oncology (Age 58)
  • Dr. Michael D. West Ph.D., Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 69)
What other stocks do shareholders of OncoCyte own?
What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.35%), Vanguard Group Inc. (4.32%), Defender Capital LLC. (2.78%), State Street Corp (1.47%), Northern Trust Corp (0.60%) and Goldman Sachs Group Inc. (0.50%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Mitchell S Levine and Ronald Asbury Andrews.
View institutional ownership trends for OncoCyte
.

Which major investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, BlackRock Inc., Nisa Investment Advisors LLC, Northern Trust Corp, State Street Corp, UBS Group AG, Renaissance Technologies LLC, and California State Teachers Retirement System.
View insider buying and selling activity for OncoCyte
or view top insider-selling stocks.

Which major investors are buying OncoCyte stock?

OCX stock was bought by a variety of institutional investors in the last quarter, including Defender Capital LLC., Vanguard Group Inc., Goldman Sachs Group Inc., Raymond James Financial Services Advisors Inc., DCF Advisers LLC, and Simplex Trading LLC. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Mitchell S Levine, and Ronald Asbury Andrews.
View insider buying and selling activity for OncoCyte
or or view top insider-buying stocks.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $1.16.

How much money does OncoCyte make?

OncoCyte has a market capitalization of $107.01 million and generates $7.73 million in revenue each year. The biotechnology company earns $-64.10 million in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does OncoCyte have?

OncoCyte employs 110 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (949) 409-7600, via email at [email protected], or via fax at 510-521-3389.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.